William Blair Issues Positive Estimate for DGX Earnings

Quest Diagnostics Incorporated (NYSE:DGX) – William Blair raised their Q3 2025 earnings per share (EPS) estimates for Quest Diagnostics in a research note issued to investors on Tuesday, October 22nd. William Blair analyst A. Brackmann now anticipates that the medical research company will post earnings per share of $2.50 for the quarter, up from their prior forecast of $2.45. The consensus estimate for Quest Diagnostics’ current full-year earnings is $8.89 per share. William Blair also issued estimates for Quest Diagnostics’ Q4 2025 earnings at $2.62 EPS and FY2025 earnings at $9.72 EPS.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Tuesday, October 22nd. The medical research company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.26 by $0.04. The company had revenue of $2.49 billion during the quarter, compared to analyst estimates of $2.43 billion. Quest Diagnostics had a return on equity of 15.35% and a net margin of 8.99%. The firm’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter last year, the firm posted $2.22 EPS.

DGX has been the topic of a number of other research reports. Barclays boosted their target price on shares of Quest Diagnostics from $154.00 to $168.00 and gave the company an “equal weight” rating in a report on Wednesday. Citigroup increased their price objective on Quest Diagnostics from $165.00 to $185.00 and gave the stock a “buy” rating in a report on Wednesday. Mizuho lifted their target price on Quest Diagnostics from $160.00 to $174.00 and gave the company an “outperform” rating in a report on Thursday. Evercore ISI started coverage on shares of Quest Diagnostics in a report on Wednesday, August 28th. They issued an “in-line” rating and a $165.00 price target on the stock. Finally, StockNews.com cut shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Wednesday. Nine equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Quest Diagnostics currently has an average rating of “Hold” and an average price target of $163.33.

Quest Diagnostics Stock Performance

NYSE DGX opened at $158.00 on Thursday. The firm has a market cap of $17.55 billion, a P/E ratio of 21.27, a price-to-earnings-growth ratio of 2.45 and a beta of 0.89. The company has a quick ratio of 0.91, a current ratio of 1.00 and a debt-to-equity ratio of 0.57. The company’s 50 day moving average is $153.05 and its 200-day moving average is $144.57. Quest Diagnostics has a 12-month low of $121.60 and a 12-month high of $160.95.

Institutional Trading of Quest Diagnostics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Rothschild Investment LLC bought a new stake in shares of Quest Diagnostics in the 2nd quarter worth approximately $26,000. Innealta Capital LLC purchased a new stake in Quest Diagnostics during the second quarter valued at about $31,000. Larson Financial Group LLC grew its stake in shares of Quest Diagnostics by 77.5% during the second quarter. Larson Financial Group LLC now owns 229 shares of the medical research company’s stock valued at $31,000 after buying an additional 100 shares during the last quarter. Riverview Trust Co purchased a new position in shares of Quest Diagnostics in the first quarter worth about $33,000. Finally, TruNorth Capital Management LLC bought a new stake in shares of Quest Diagnostics in the 2nd quarter valued at about $33,000. Hedge funds and other institutional investors own 88.06% of the company’s stock.

Insider Transactions at Quest Diagnostics

In related news, SVP Karthik Kuppusamy sold 1,990 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $153.26, for a total value of $304,987.40. Following the transaction, the senior vice president now owns 11,459 shares of the company’s stock, valued at $1,756,206.34. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.79% of the stock is currently owned by insiders.

Quest Diagnostics Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, October 21st. Stockholders of record on Friday, October 4th were given a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a dividend yield of 1.90%. The ex-dividend date of this dividend was Friday, October 4th. Quest Diagnostics’s dividend payout ratio (DPR) is currently 40.38%.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.